Quantitative high-throughput single-cell cytotoxicity assay for T cells.

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Cancer immunotherapy, particularly adoptive cell therapy (ACT) using chimeric antigen receptor (CAR) T cells, shows promise in clinical trials.
• CAR(+) T cells offer advantages like MHC-independent targeting and controllable in vivo functions.
• Linking pre-infusion T cell characteristics to clinical efficacy requires robust in vitro functional assays.

Purpose of the Study:

• To develop and present a high-throughput methodology for monitoring T-cell mediated cytotoxicity at the single-cell level.
• To enable detailed analysis of cytolytic functionality for optimizing T-cell based therapies.
• To bridge the gap between molecular/functional T cell features and clinical outcomes in ACT.

Main Methods:

• Utilized microfabricated arrays in polydimethylsiloxane (PDMS) for spatial confinement of effector and target cells.
• Employed automated time-lapse fluorescence microscopy to monitor thousands of effector-target interactions simultaneously.
• Developed a high-throughput assay for single-cell level assessment of T-cell mediated cytotoxicity.

Main Results:

• The presented methodology allows for high-throughput monitoring of T-cell mediated cytotoxicity at the single-cell level.
• This approach overcomes limitations of standard flow cytometry in assessing conjugate formation, lifetimes, and multi-target killing.
• The technique is broadly applicable for studying cytolytic functionality of T cells in various contexts.

Conclusions:

• The developed high-throughput methodology is essential for advancing T-cell based adoptive cell therapy.
• This assay provides critical insights into T-cell effector functions, aiding in the design of next-generation cancer immunotherapies.
• This technique facilitates the link between in vitro T-cell functionality and in vivo clinical efficacy.